Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.
| Autor: | Hoffmann FA; Department of Neurology, Hospital Martha-Maria Halle-Dölau, Halle, Germany., Trenova A; Department of Neurology, Medical University of Plovdiv, Plovdiv, Bulgaria., Llaneza MA; Neurology Department, Ferrol University Hospital, Ferrol, Spain., Fischer J; Neurologische Praxis (NTDStudy-Group), Lappersdorf, Germany., Lus G; Multiple Sclerosi Center university of Campania L. Vanvitelli, Naples, Italy., von Bredow D; QuintilesIMS, IMS Health GmbH & Co. OHG, Munich, Germany., Lara N; QuintilesIMS, Barcelona, Spain., Lam E; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Van Hoef M; Novartis Pharma AG, Fabrikstrasse 12-3.03.12, Postfach, CH-4002, Basel, Switzerland., Bakshi R; Novartis Pharma AG, Fabrikstrasse 12-3.03.12, Postfach, CH-4002, Basel, Switzerland. rajesh.bakshi@novartis.com. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | BMC neurology [BMC Neurol] 2017 Aug 09; Vol. 17 (1), pp. 156. Date of Electronic Publication: 2017 Aug 09. |
| DOI: | 10.1186/s12883-017-0928-9 |
| Abstrakt: | Background: Patients with multiple sclerosis (MS) receiving long-term, subcutaneous interferon β-1b (IFN β-1b; Extavia®) often experience injection-site reactions and injection-site pain, which together with other side-effects (such as flu-like symptoms) result in suboptimal treatment compliance/adherence. The EXCHANGE study evaluated patient satisfaction with IFN β-1b treatment, administered using ExtaviPro™ 30G, a new auto-injector, in a real-world setting. Methods: This 26-week, open-label, prospective, non-interventional, observational, multi-country multi-centre study enrolled patients with MS who had been treated with IFN β-1b or other disease-modifying therapies with a self-administered auto-injector for ≥3 months and who were planned to switch to IFN β-1b treatment administered using ExtaviPro™ 30G as part of routine clinical care. Patient-reported outcomes included overall patient satisfaction (primary outcome) and satisfaction associated with treatment effectiveness, convenience and side-effects, assessed using Treatment Satisfaction Questionnaire for Medication (TSQM)-14. The changes in TSQM scores from baseline to Week 26 were reported. All data were analysed using SAS statistical software (version 9.4). Results: Of the 336 patients enrolled, 324 were included in the analysis. At baseline, mean ± standard deviation (SD) age of patients was 41.8 ± 11.3 years and 68.2% were women. The mean ± SD of MS disease duration was 6.9 ± 6.6 years, and the majority of patients (94.1%) had relapsing-remitting MS. The mean ± SD of TSQM score for overall patient satisfaction at Week 26 was 75.6 ± 16.46 (baseline, 73.0 ± 17.14; p = 0.0342). The mean ± SD of TSQM subscale scores for patient satisfaction with effectiveness, side-effects and convenience were 75.0 ± 18.65 (baseline, 71.6 ± 19.45; p = 0.0356), 88.5 ± 18.98 (baseline, 82.7 ± 22.93; p = 0.0002) and 77.6 ± 16.72 (baseline, 71.1 ± 17.53; p < 0.0001), respectively. Conclusion: The results from this real-world study suggest that administering IFN β-1b with the new ExtaviPro™ auto-injector significantly improves overall patient satisfaction, including satisfaction associated with effectiveness, side-effects and convenience in MS patients. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|